Multiple Sclerosis Therapeutic Market size is estimated at USD 26.4 billion in 2024 and is likely to exceed USD 46.8 billion by the end of 2037, growing at over 4.9% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of multiple sclerosis therapeutic is evaluated at USD 29 billion. The increasing prevalence of multiple sclerosis globally with its rising awareness is leading to earlier diagnosis and treatment. Advancements in medical research have further resulted in the development of innovative therapies, including biologics, monoclonal antibodies, and oral treatments. These treatments offer improved efficacy and patient convenience.
As per an article posted by WHO in August 2023, over 1.8 million people around the world suffer from multiple sclerosis (MS). The disease is primarily common among young adults and females. Several companies are engaging in R&D to accelerate the development and launch of next-generation treatments to address this rising concern. For instance, in December 2022, the U.S. FDA approved Briumvi to treat adults suffering from relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS. In February 2024, Neuraxpharm Group announced the launch of Briumvi in Europe. Additionally, the trend toward personalized medicines is gaining traction as patients and healthcare providers seek more tailored therapeutic approaches.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.9% |
|
Base Year Market Size (2024) |
USD 26.4 billion |
|
Forecast Year Market Size (2037) |
USD 46.8 billion |
|
Regional Scope |
|
Route of Administration (Oral, Injectables)
In route of administration, oral segment is set to hold multiple sclerosis therapeutic market share of more than 58.5% by 2037. It is easier to monitor oral medications than injectable therapies, making a patient more compliant and convenient. The patients are allowed to take medication at home, in the absence of any medical supervision, thus enhancing their treatment process.
This convenience leads to adherence to the treatment routine, which is critical in chronic conditions including multiple sclerosis, as it demands a thorough treatment to manage symptoms, thereby, slowing disease progression. Moreover, continuous innovation in oral formulations, with improved safety profiles and efficacy in treating both relapsing and progressive MS, has further solidified their dominance in the market. For instance, in March 2019, the U.S. FDA approved Novartis’ Mayzent tablets to treat adults with relapsing forms of multiple sclerosis.
Distribution Channel (Hospital pharmacy, Retail pharmacy, Online Pharmacy)
In distribution channel, the hospital segment in multiple sclerosis therapeutic market is projected to witness a considerable growth during the forecast period, owing to their central role in diagnosing, managing, and treating the disease. Hospitals serve as key points for the administration of high-cost and complex therapies, including biologics, and monoclonal antibodies. These often need specialist supervision, and intravenous delivery in some cases. In addition, hospitals have necessary infrastructure for administering treatments that require refrigeration and specialized handling, making them a preferred channel for distributing these advanced therapies. Furthermore, hospitals tend to offer comprehensive care, including physical therapy, counseling, and access to multidisciplinary teams, positioning them as dominant players in the multiple sclerosis therapeutic market.
Our in-depth analysis of the global market includes the following segments:
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
North America Market Analysis
The North America multiple sclerosis therapeutic market is the largest and most advanced, owing to high disease prevalence, well-established healthcare infrastructure, and the presence of significant market players. The region also benefits from strong regulatory support for innovative therapies and a growing focus on personalized medicines. Advanced treatments such as biologics, oral drugs, and monoclonal antibodies are widely available, making the market highly competitive. In November 2023, the National Multiple Sclerosis Society invested USD 4.4 million in multi-year funding to launch new MS research projects. Such funds and grants are also boosting the multiple sclerosis therapeutic market in the region.
U.S. holds the largest share in North America market and is primarily driven by a strong pipeline of innovative treatments, including next-generation biologics, supported by FDA approvals and expedited regulatory pathways for breakthroughs. Additionally, the high prevalance of MS in the U.S. is also driving the multiple sclerosis therapeutic market growth in the country. As per the National Multiple Sclerosis Society, almost 1 million people in the United States were diagnosed with MS in 2019. The rising number of cases in the country, in addition to growing trend for personalized medicines, is boosting the market growth significantly.
Canada multiple sclerosis therapeutic market is driven by the country’s relatively high prevalance of the disease, particularly in provinces such as Alberta and Saskatchewan. As per an article by the Government of Canada, nearly 290 out of every 100,000 Canadians aged 20 years and above was living with MS from 2021 to 2022, and 7 out of 10 are women. The government funded healthcare system plays a central role in treatment access, with reimbursement policies significantly influencing the availability of therapies. Public awareness and early diagnosis initiatives, supported by organizations such as Multiple Sclerosis Society of Canada is also driving the country’s market growth significantly.
Europe Market Statistics
The region is witnessing growing adoption of advanced therapies, and strong regulatory frameworks. While biologics and oral therapies are widely available, the region faces challenges related to pricing and varying reimbursement policies across the countries. The entry of biosimilars and generics is also shaping the multiple sclerosis therapeutic market dynamics, offering cost-effective alternatives to expensive branded drugs. In June 2024, the European Commission approved the anti-CD20 therapy, the first twice-yearly injection for relapsing and primary progressive multiple sclerosis (RMS and PPMS). These factors are further boosting the region’s market growth.
UK is largely driven by the National Health Service which provides wide access to MS treatments. The multiple sclerosis therapeutic market is also supported by a well-established network of MS clinics, and specialists, making it a leading player in early diagnosis and long-term management. In July 2024, the UK Government released a report stating that the Medicines and Healthcare Products Regulatory Agency (MHRA) approved a new formulation of the medicine ocrelizumab (Ocrevus 920mg solution for injection). It is aimed to treat relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in adults.
France witnesses a strong demand for both oral and injectable therapies, owing to the rising prevalence of MS. French regulatory bodies, such as the Haute Autorite de Sante (HAS) plays a key role in assessing the cost-effectiveness of MS therapies, influencing the availability of advanced treatments. As per a report by the National Institutes of Health, in France, the highest prevalence rates were observed in the northeastern regions and the lowest rates in the southwestern regions. Nearly, 51.8% of the population received at least one MS-specific drug in 2021. These rising cases are projected to further accelerate the multiple sclerosis therapeutic market growth by 2037.
Companies in the multiple sclerosis therapeutics adopting several strategies to strengthen their position and enhance their product portfolios. Extensive investment in R&D activities, and launching innovative new treatments, particularly in biologics and oral therapies are two of the highly adopted strategies. Companies are also focusing on securing regulatory approvals for new drugs. Collaboration and acquisition activities are maintaining the competition in the global multiple sclerosis therapeutic market. For instance, in October 2020, Eli Lilly and Company announced the acquisition of Disarm Therapeutics for an upfront payment of $135.0 million. Some of the prominent players include:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?